We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of Systemic and Intranasal BCG Treatment in Experimental Allergic Rhinitis-Induced Rats.
- Authors
Türker, Cihan; Keleş, Erol; Kaygusuz, irfan; Karlıdağ, Turgut; Akyiğit, Abdulvahap; Artaş, Gökhan; Kuloğlu, Tuncay; ilhan, Nevin; Yalçın, Şinasi
- Abstract
Objective: To investigate the efficacy of intranasally (topical) and systemically Bacillus Calmette-Guerin (BCG) in the treatment of allergic rhinitis in an allergic rhinitis model. Methods: All rats included in the study were divided into six groups. Each group had seven animals. Group A, was the Control Group, Group B included allergic rhinitis-induced rats, Group C included topical BCG treated ones, Group D included systemic BCG treated ones, Group E consisted of rats with allergic rhinitis treated with intranasal BCG and Group F had rats with allergic rhinitis which treated with systemic BCG. Study groups B, E, F were administered intraperitoneal ovalbumin every other day for 14 days to induce allergic rhinitis. As of the 15th day, these ones were provoked with a daily dose of intranasal ovalbumin for 15 days. As of the 15th day, Group E was given intranasal BCG daily for two weeks, 1 hour after intranasal ovalbumin was administered. Group F was given a daily dose of systemic BCG for seven weeks starting two weeks before the allergy was induced. Blood samples were taken 24 hours after the end of the study and tested for ELISA, IL-4, IL-5 and IFN-γ. Also, nasal mucosae were harvested after the rats were sacrificed and stored for histopathologic examination. Results: In the two groups in which rats were induced with allergic rhinitis and treated with systemic BCG or topical BCG, histopathologic evaluation scores (increase in goblet cells, increase in connective tissue, vascular congestion, vascular proliferation, inflammatory cell infiltration, eosinophil infiltration) were significantly decreased compared to the Allergy Group. No significant difference was identified between these two treatment groups in terms of their histopathologic evaluation scores (p>0.05). No significant differences were identified between the Allergy Group and the group treated with topical BCG or the group treated with systemic BCG with respect to serum IL- 4, IL-5 and IFN- γ (p>0.05). Conclusion: The results of this study show that BCG reduces allergic inflammation at tissue level and may be an alternative treatment option for allergic rhinitis. Considering that allergic rhinitis is a disease affecting approximately 25-35% of the population, it is evident that further studies are needed on this subject.
- Subjects
INVESTIGATIONAL therapies; RATS; CONNECTIVE tissues; ALLERGIC rhinitis; BLOOD sampling; ALLERGIES
- Publication
Turkish Archives of Otolaryngology / Türk Otolarengoloji Arsivi, 2019, Vol 57, pS5
- ISSN
0304-4793
- Publication type
Article
- DOI
10.5152/tao.2019.20012